Methods and compositions for treating multiple myeloma
Methods and compositions for sensitizing multiple myeloma cells to treatment with IMiDs are provided. Aspects include methods of administering AR-42 and an IMiD (e.g., lenalidomide, pomalidomide) to multiple myeloma patients.
1. A method of sensitizing multiple myeloma cells to treatment with lenalidomide comprising administering AR-42 and lenalidomide to a patient in need treatment in an amount sufficient to achieve a blood or tissue concentration of at least about 0.5 to about 1 μM of AR-42 and at least about 391 to about 568 ng/ml of lenalidomide.
2. The method of claim 1 , wherein the amount of AR-42 administered to the patient is about 40 to 70 mg in a single dose or divided dose, three times per week for three weeks out of a 28 day cycle.
3. The method of claim 2 , wherein the amount of AR-42 administered to the patient is about 0.6 to about 1.1 mg/kg of the patient.
4. The method claim 2 , wherein the amount of lenalidomide administered to the patient is about 25 mg per day for days 1-21 of a 28 day cycle.
5. A method of treating a mammal with multiple myeloma comprising administering AR-42 and an immunomodulatory agent selected from the group consisting of lenalidomide and pomolidomide to the mammal.
6. The method of claim 5 , wherein the amount of AR-42 administered to the mammal is about 40 to 70 mg in a single dose or divided dose, three times per week for three weeks out of a 28 day cycle.
7. The method of claim 6 , wherein the amount of AR-42 administered to the patient is about 0.6 to about 1.1 mg/kg of the patient.
8. The method of claim 5 , wherein AR-42 and the immunomodulatory agent are co-administered to the mammal.
9. The method of claim 5 , wherein AR-42 is administered before administering the immunomodulatory agent.
10. The method of claim 5 , wherein the immunomodulatory agent is administered before administering AR-42.
11. The method of claim 5 , where the amount of lenalidomide administered to the mammal is about 25 mg per day for days 1-21 of a 28 day cycle.
12. The method of claim 5 , where the amount of pomalidomide administered to the mammal is about 4 mg per day for days 1-21 of a 28 day cycle.